



◆ QHJ14s04/AB II-KO-11

(QHJI; iPS cells expressing the highest HLA in Japan <sup>(\*1)</sup>)

<b>Clone ID</b>	QHJ14s04/AB II-KO-11	<b>Product</b>	Human iPS cells
<b>Source</b>	Peripheral Blood, Human	<b>Race</b>	Japanese
<b>Passage No.</b>	22	<b>Gender</b>	Male
<b>Label Name</b>	Fit__13SKC(QHJ14)-230307	<b>Manufacture Dates</b>	27-Mar-2023
<b>Culture medium</b>	StemFit AK03N	<b>Substrate</b>	iMatrix-511MG
<b>Culture Method</b>	Feeder-free <sup>(*2)</sup>		
<b>Genome-editing techniques</b>	CRISPR-Cas9 <sup>(*2)</sup>		
<b>Use and Provision of this cell stock</b>	Please check our web site ; <a href="https://www.cira-foundation.or.jp/e/project/index.html">https://www.cira-foundation.or.jp/e/project/index.html</a>		

(\*1) **Reference**; Okita, *et. al.*, Nat Methods. 2011 8(5): 409-412

(\*2) **Reference**; Huaigeng Xu, *et al.* Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility. Cell Stem Cell. 2019 Apr 4;24(4):566-578.

## Test Result

Test	Method	Result
<b>Sterility</b>	Direct Inoculation Method	Negative
<b>Mycoplasma</b>	PCR	Negative
<b>Endotoxin</b>	LAL	< 0.018 EU/mL
<b>Virology (HBV, HCV, HIV, HTLV, ParvoB19)</b>	PCR	Negative
<b>Morphology</b>	Microscope	Consistent with human ES cells
<b>Thawed postnatal cells</b>	Cell count	2.58 x 10 <sup>5</sup> cells (Survival rate; 88.3 %)
<b>STR genotyping</b>	PCR	Consistent with the donor cells
<b>Undifferentiated markers</b>	Flow cytometry	TRA-1-60(+): 98.2 % SSEA4(+); 99.7 % TRA-2-49(+); 98.9 % OCT3/4(+); 98.4 %
<b>Gene editing confirmation</b>	WGS	Detected of edits
	Flow cytometry <sup>(*6)</sup>	HLA-A(-); 99.4 % HLA-C(+); 94.8 %
<b>Karyotype</b>	G-banding	46,XY[20]
<b>CNV<sup>(*3)</sup> (*6)</b>	WGS, SNP	No de novo CNVs (>1kbp) were found in COSMIC Cancer Gene Census (ver.96) and Shibata list <sup>(*4)</sup> .
<b>SNV/Indel<sup>(*3)</sup> (*6)</b>	WGS	No de-novo non-synonymous SNVs/Indels were found in COSMIC Cancer Gene Census (ver.96) and Shibata list <sup>(*4)</sup> .
<b>Residual guide RNA<sup>(*6)</sup></b>	qPCR	Not detected
<b>Residual Cas9<sup>(*6)</sup></b>	ELISA	0.538 ng/mL <sup>(*7)</sup>
<b>Cardiac differentiation<sup>(*6)</sup></b>	Reference: "Funakoshi et al., 2016, Sci Rep."	TnT(+) = 59.2 %
<b>Number of proliferating cells after thawing</b>	Counting the number of the cells after culturing for 6 days <sup>(*5)</sup> .	20.58 × 10 <sup>5</sup> cells (Number of seeded cells : 0.78 × 10 <sup>5</sup> cells)

(\*3) CNV; Copy Number Variation , SNV/Indel; Single nucleotide variants /Insertion Deletion

(\*4) The PMDA Science Board "Current Perspective on Evaluation of Tumorigenicity of Cellular- and Tissue-based Products Derived from induced Pluripotent Stem Cells (iPSCs) and iPSCs as Their Starting Materials" (Cellular- and Tissue-based Products Subcommittee, 20 August 2013)

(\*5) NucleoCounter® NC200


(\*6) Reference test: these are not related to the product release.

(\*7) As a reference, the residual value of Cas9 in the cells immediately after transfection: 6~34 ng/mL

In the negative control: 1 ng/mL.



■ Image



Scale bar: 50  $\mu$ m

Please contact us if you have any questions.

([ips-request@cira-foundation.or.jp](mailto:ips-request@cira-foundation.or.jp))



Reprint or reproduction of this page without permission is prohibited.